Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Nicotinic Acid for the Treatment of Alzheimer's Disease — Stella

Home/Alzheimer Disease/Nicotinic Acid for the Treatment of Alzheimer's Disease

View on ClinicalTrials.gov

Recruiting

Back to Alzheimer Disease trials

Nicotinic Acid for the Treatment of Alzheimer's Disease

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

IU Health Neuroscience Center, Indianapolis, Indiana

Key details

Phase

Early testing / Safety & dosing

Sponsor

Indiana University

Collaborators

Alzheimer's Association

Enrollment target

~30 participants

Started

December 2024

Primary completion

December 2026

Age range

60 Years – 85 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.